Loading…

Real‐life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling

We report a real‐life 3D therapy failure in a patient treated with ombitasvir (OMV)/paritaprevir/ritonavir and dasabuvir without ribavirin (3D‐R). He had therapy failure at week 12 after the end of treatment. We detected resistance‐associated substitutions (RASs) plus polymorphisms on NS3, NS5A, and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical virology 2018-07, Vol.90 (7), p.1257-1263
Main Authors: Marascio, Nadia, Pavia, Grazia, Romeo, Isabella, Talarico, Carmine, Di Salvo, Sebastiano, Reale, Mariaconcetta, Marano, Vito, Barreca, Giorgio Settimo, Fabiani, Fernanda, Perrotti, Nicola, De Siena, Massimo, Giancotti, Francesca, Gravina, Tiziana, Alcaro, Stefano, Artese, Anna, Torti, Carlo, Liberto, Maria Carla, Focà, Alfredo
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3533-8d184a22221407a77f722adac65bff63d378a21b0b47263149572c6f9a6ac4573
cites cdi_FETCH-LOGICAL-c3533-8d184a22221407a77f722adac65bff63d378a21b0b47263149572c6f9a6ac4573
container_end_page 1263
container_issue 7
container_start_page 1257
container_title Journal of medical virology
container_volume 90
creator Marascio, Nadia
Pavia, Grazia
Romeo, Isabella
Talarico, Carmine
Di Salvo, Sebastiano
Reale, Mariaconcetta
Marano, Vito
Barreca, Giorgio Settimo
Fabiani, Fernanda
Perrotti, Nicola
De Siena, Massimo
Giancotti, Francesca
Gravina, Tiziana
Alcaro, Stefano
Artese, Anna
Torti, Carlo
Liberto, Maria Carla
Focà, Alfredo
description We report a real‐life 3D therapy failure in a patient treated with ombitasvir (OMV)/paritaprevir/ritonavir and dasabuvir without ribavirin (3D‐R). He had therapy failure at week 12 after the end of treatment. We detected resistance‐associated substitutions (RASs) plus polymorphisms on NS3, NS5A, and NS5B target regions by population sequencing (15% cut‐off) at baseline, at relapse and during follow‐up. About this, NS5A RASs generally persist longer than resistances in the other target genes and may impact treatment outcome. Therefore, to evaluate OMV drug‐resistance mechanism, we studied the acquired RAS plus polymorphisms on NS5A phosphoprotein by computational studies. OMV showed a higher affinity towards baseline and 93H/108 K mutant structure (follow‐up) with respect to 93H/R108 mutant structure (relapse) on phosphoprotein. By Molecular Dynamics simulations (MDs), structural information about the protein stability in presence of OMV were observed. According to our data, molecular modeling approach has proved to be a powerful method to evaluate the impact of these RASs plus specific amino acid (AA) changes on phosphoprotein.
doi_str_mv 10.1002/jmv.25073
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2018662766</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2018662766</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3533-8d184a22221407a77f722adac65bff63d378a21b0b47263149572c6f9a6ac4573</originalsourceid><addsrcrecordid>eNp1kc1u1DAQgK0K1C6FAy-ARuJSDmnHdmIn3FYtUGgBqT9cIyexWa_sdWpvWnKDN-AZeRKy3cIBCV_Gh0-fNPMR8pziIUVkR0t_e8gKlHyHzChWIqtQ0kdkhjQXmRC02CNPUloiYlkxtkv2WFXIAgXOyI8Lrdyv7z-dNRr4CawXOqp-BKOsG6J-DfOVcmOyCYKBT5fFHCp-ChfzS-jdkIBiCWfQBzf6EPuFTR7sCtrge6e_wZ1dLyD4xq5VurURmhF8cLodnIrTr9POrr4-JY-Nckk_e5j75Prtm6vj0-z887v3x_PzrOUF51nZ0TJXbHo0R6mkNJIx1alWFI0xgndclorRBptcMsFpPq3IWmEqJVSbF5Lvk4Ott4_hZtBpXXubWu2cWukwpJohLYVgUogJffkPugxDnA6xoXKZcyzpRvhqS7UxpBS1qftovYpjTbHedKmnLvV9l4l98WAcGq-7v-SfEBNwtAXurNPj_031h49ftsrfg4eVjw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2047430817</pqid></control><display><type>article</type><title>Real‐life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Marascio, Nadia ; Pavia, Grazia ; Romeo, Isabella ; Talarico, Carmine ; Di Salvo, Sebastiano ; Reale, Mariaconcetta ; Marano, Vito ; Barreca, Giorgio Settimo ; Fabiani, Fernanda ; Perrotti, Nicola ; De Siena, Massimo ; Giancotti, Francesca ; Gravina, Tiziana ; Alcaro, Stefano ; Artese, Anna ; Torti, Carlo ; Liberto, Maria Carla ; Focà, Alfredo</creator><creatorcontrib>Marascio, Nadia ; Pavia, Grazia ; Romeo, Isabella ; Talarico, Carmine ; Di Salvo, Sebastiano ; Reale, Mariaconcetta ; Marano, Vito ; Barreca, Giorgio Settimo ; Fabiani, Fernanda ; Perrotti, Nicola ; De Siena, Massimo ; Giancotti, Francesca ; Gravina, Tiziana ; Alcaro, Stefano ; Artese, Anna ; Torti, Carlo ; Liberto, Maria Carla ; Focà, Alfredo</creatorcontrib><description>We report a real‐life 3D therapy failure in a patient treated with ombitasvir (OMV)/paritaprevir/ritonavir and dasabuvir without ribavirin (3D‐R). He had therapy failure at week 12 after the end of treatment. We detected resistance‐associated substitutions (RASs) plus polymorphisms on NS3, NS5A, and NS5B target regions by population sequencing (15% cut‐off) at baseline, at relapse and during follow‐up. About this, NS5A RASs generally persist longer than resistances in the other target genes and may impact treatment outcome. Therefore, to evaluate OMV drug‐resistance mechanism, we studied the acquired RAS plus polymorphisms on NS5A phosphoprotein by computational studies. OMV showed a higher affinity towards baseline and 93H/108 K mutant structure (follow‐up) with respect to 93H/R108 mutant structure (relapse) on phosphoprotein. By Molecular Dynamics simulations (MDs), structural information about the protein stability in presence of OMV were observed. According to our data, molecular modeling approach has proved to be a powerful method to evaluate the impact of these RASs plus specific amino acid (AA) changes on phosphoprotein.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.25073</identifier><identifier>PMID: 29575060</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Aged ; Amino acid sequence ; Anilides - pharmacology ; Antiviral Agents - pharmacology ; Carbamates - pharmacology ; computational analysis ; Computer applications ; Computer simulation ; docking ; Dynamic stability ; Failure analysis ; HCV phosphoprotein ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - virology ; Humans ; Male ; Models, Molecular ; Molecular chains ; Molecular dynamics ; Molecular Dynamics Simulation ; molecular dynamics simulations ; Molecular modelling ; Molecular structure ; Mutation, Missense ; Polymorphism ; Polymorphism, Genetic ; Proline ; Proteins ; Recurrence ; resistance‐associated substitutions ; Ribavirin ; Ritonavir ; Therapy ; Treatment Failure ; Valine ; Viral Nonstructural Proteins - chemistry ; Viral Nonstructural Proteins - genetics ; Virology</subject><ispartof>Journal of medical virology, 2018-07, Vol.90 (7), p.1257-1263</ispartof><rights>2018 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3533-8d184a22221407a77f722adac65bff63d378a21b0b47263149572c6f9a6ac4573</citedby><cites>FETCH-LOGICAL-c3533-8d184a22221407a77f722adac65bff63d378a21b0b47263149572c6f9a6ac4573</cites><orcidid>0000-0003-0880-8955</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29575060$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marascio, Nadia</creatorcontrib><creatorcontrib>Pavia, Grazia</creatorcontrib><creatorcontrib>Romeo, Isabella</creatorcontrib><creatorcontrib>Talarico, Carmine</creatorcontrib><creatorcontrib>Di Salvo, Sebastiano</creatorcontrib><creatorcontrib>Reale, Mariaconcetta</creatorcontrib><creatorcontrib>Marano, Vito</creatorcontrib><creatorcontrib>Barreca, Giorgio Settimo</creatorcontrib><creatorcontrib>Fabiani, Fernanda</creatorcontrib><creatorcontrib>Perrotti, Nicola</creatorcontrib><creatorcontrib>De Siena, Massimo</creatorcontrib><creatorcontrib>Giancotti, Francesca</creatorcontrib><creatorcontrib>Gravina, Tiziana</creatorcontrib><creatorcontrib>Alcaro, Stefano</creatorcontrib><creatorcontrib>Artese, Anna</creatorcontrib><creatorcontrib>Torti, Carlo</creatorcontrib><creatorcontrib>Liberto, Maria Carla</creatorcontrib><creatorcontrib>Focà, Alfredo</creatorcontrib><title>Real‐life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling</title><title>Journal of medical virology</title><addtitle>J Med Virol</addtitle><description>We report a real‐life 3D therapy failure in a patient treated with ombitasvir (OMV)/paritaprevir/ritonavir and dasabuvir without ribavirin (3D‐R). He had therapy failure at week 12 after the end of treatment. We detected resistance‐associated substitutions (RASs) plus polymorphisms on NS3, NS5A, and NS5B target regions by population sequencing (15% cut‐off) at baseline, at relapse and during follow‐up. About this, NS5A RASs generally persist longer than resistances in the other target genes and may impact treatment outcome. Therefore, to evaluate OMV drug‐resistance mechanism, we studied the acquired RAS plus polymorphisms on NS5A phosphoprotein by computational studies. OMV showed a higher affinity towards baseline and 93H/108 K mutant structure (follow‐up) with respect to 93H/R108 mutant structure (relapse) on phosphoprotein. By Molecular Dynamics simulations (MDs), structural information about the protein stability in presence of OMV were observed. According to our data, molecular modeling approach has proved to be a powerful method to evaluate the impact of these RASs plus specific amino acid (AA) changes on phosphoprotein.</description><subject>Aged</subject><subject>Amino acid sequence</subject><subject>Anilides - pharmacology</subject><subject>Antiviral Agents - pharmacology</subject><subject>Carbamates - pharmacology</subject><subject>computational analysis</subject><subject>Computer applications</subject><subject>Computer simulation</subject><subject>docking</subject><subject>Dynamic stability</subject><subject>Failure analysis</subject><subject>HCV phosphoprotein</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - virology</subject><subject>Humans</subject><subject>Male</subject><subject>Models, Molecular</subject><subject>Molecular chains</subject><subject>Molecular dynamics</subject><subject>Molecular Dynamics Simulation</subject><subject>molecular dynamics simulations</subject><subject>Molecular modelling</subject><subject>Molecular structure</subject><subject>Mutation, Missense</subject><subject>Polymorphism</subject><subject>Polymorphism, Genetic</subject><subject>Proline</subject><subject>Proteins</subject><subject>Recurrence</subject><subject>resistance‐associated substitutions</subject><subject>Ribavirin</subject><subject>Ritonavir</subject><subject>Therapy</subject><subject>Treatment Failure</subject><subject>Valine</subject><subject>Viral Nonstructural Proteins - chemistry</subject><subject>Viral Nonstructural Proteins - genetics</subject><subject>Virology</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kc1u1DAQgK0K1C6FAy-ARuJSDmnHdmIn3FYtUGgBqT9cIyexWa_sdWpvWnKDN-AZeRKy3cIBCV_Gh0-fNPMR8pziIUVkR0t_e8gKlHyHzChWIqtQ0kdkhjQXmRC02CNPUloiYlkxtkv2WFXIAgXOyI8Lrdyv7z-dNRr4CawXOqp-BKOsG6J-DfOVcmOyCYKBT5fFHCp-ChfzS-jdkIBiCWfQBzf6EPuFTR7sCtrge6e_wZ1dLyD4xq5VurURmhF8cLodnIrTr9POrr4-JY-Nckk_e5j75Prtm6vj0-z887v3x_PzrOUF51nZ0TJXbHo0R6mkNJIx1alWFI0xgndclorRBptcMsFpPq3IWmEqJVSbF5Lvk4Ott4_hZtBpXXubWu2cWukwpJohLYVgUogJffkPugxDnA6xoXKZcyzpRvhqS7UxpBS1qftovYpjTbHedKmnLvV9l4l98WAcGq-7v-SfEBNwtAXurNPj_031h49ftsrfg4eVjw</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Marascio, Nadia</creator><creator>Pavia, Grazia</creator><creator>Romeo, Isabella</creator><creator>Talarico, Carmine</creator><creator>Di Salvo, Sebastiano</creator><creator>Reale, Mariaconcetta</creator><creator>Marano, Vito</creator><creator>Barreca, Giorgio Settimo</creator><creator>Fabiani, Fernanda</creator><creator>Perrotti, Nicola</creator><creator>De Siena, Massimo</creator><creator>Giancotti, Francesca</creator><creator>Gravina, Tiziana</creator><creator>Alcaro, Stefano</creator><creator>Artese, Anna</creator><creator>Torti, Carlo</creator><creator>Liberto, Maria Carla</creator><creator>Focà, Alfredo</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0880-8955</orcidid></search><sort><creationdate>201807</creationdate><title>Real‐life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling</title><author>Marascio, Nadia ; Pavia, Grazia ; Romeo, Isabella ; Talarico, Carmine ; Di Salvo, Sebastiano ; Reale, Mariaconcetta ; Marano, Vito ; Barreca, Giorgio Settimo ; Fabiani, Fernanda ; Perrotti, Nicola ; De Siena, Massimo ; Giancotti, Francesca ; Gravina, Tiziana ; Alcaro, Stefano ; Artese, Anna ; Torti, Carlo ; Liberto, Maria Carla ; Focà, Alfredo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3533-8d184a22221407a77f722adac65bff63d378a21b0b47263149572c6f9a6ac4573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Amino acid sequence</topic><topic>Anilides - pharmacology</topic><topic>Antiviral Agents - pharmacology</topic><topic>Carbamates - pharmacology</topic><topic>computational analysis</topic><topic>Computer applications</topic><topic>Computer simulation</topic><topic>docking</topic><topic>Dynamic stability</topic><topic>Failure analysis</topic><topic>HCV phosphoprotein</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - virology</topic><topic>Humans</topic><topic>Male</topic><topic>Models, Molecular</topic><topic>Molecular chains</topic><topic>Molecular dynamics</topic><topic>Molecular Dynamics Simulation</topic><topic>molecular dynamics simulations</topic><topic>Molecular modelling</topic><topic>Molecular structure</topic><topic>Mutation, Missense</topic><topic>Polymorphism</topic><topic>Polymorphism, Genetic</topic><topic>Proline</topic><topic>Proteins</topic><topic>Recurrence</topic><topic>resistance‐associated substitutions</topic><topic>Ribavirin</topic><topic>Ritonavir</topic><topic>Therapy</topic><topic>Treatment Failure</topic><topic>Valine</topic><topic>Viral Nonstructural Proteins - chemistry</topic><topic>Viral Nonstructural Proteins - genetics</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marascio, Nadia</creatorcontrib><creatorcontrib>Pavia, Grazia</creatorcontrib><creatorcontrib>Romeo, Isabella</creatorcontrib><creatorcontrib>Talarico, Carmine</creatorcontrib><creatorcontrib>Di Salvo, Sebastiano</creatorcontrib><creatorcontrib>Reale, Mariaconcetta</creatorcontrib><creatorcontrib>Marano, Vito</creatorcontrib><creatorcontrib>Barreca, Giorgio Settimo</creatorcontrib><creatorcontrib>Fabiani, Fernanda</creatorcontrib><creatorcontrib>Perrotti, Nicola</creatorcontrib><creatorcontrib>De Siena, Massimo</creatorcontrib><creatorcontrib>Giancotti, Francesca</creatorcontrib><creatorcontrib>Gravina, Tiziana</creatorcontrib><creatorcontrib>Alcaro, Stefano</creatorcontrib><creatorcontrib>Artese, Anna</creatorcontrib><creatorcontrib>Torti, Carlo</creatorcontrib><creatorcontrib>Liberto, Maria Carla</creatorcontrib><creatorcontrib>Focà, Alfredo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marascio, Nadia</au><au>Pavia, Grazia</au><au>Romeo, Isabella</au><au>Talarico, Carmine</au><au>Di Salvo, Sebastiano</au><au>Reale, Mariaconcetta</au><au>Marano, Vito</au><au>Barreca, Giorgio Settimo</au><au>Fabiani, Fernanda</au><au>Perrotti, Nicola</au><au>De Siena, Massimo</au><au>Giancotti, Francesca</au><au>Gravina, Tiziana</au><au>Alcaro, Stefano</au><au>Artese, Anna</au><au>Torti, Carlo</au><au>Liberto, Maria Carla</au><au>Focà, Alfredo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real‐life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J Med Virol</addtitle><date>2018-07</date><risdate>2018</risdate><volume>90</volume><issue>7</issue><spage>1257</spage><epage>1263</epage><pages>1257-1263</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><abstract>We report a real‐life 3D therapy failure in a patient treated with ombitasvir (OMV)/paritaprevir/ritonavir and dasabuvir without ribavirin (3D‐R). He had therapy failure at week 12 after the end of treatment. We detected resistance‐associated substitutions (RASs) plus polymorphisms on NS3, NS5A, and NS5B target regions by population sequencing (15% cut‐off) at baseline, at relapse and during follow‐up. About this, NS5A RASs generally persist longer than resistances in the other target genes and may impact treatment outcome. Therefore, to evaluate OMV drug‐resistance mechanism, we studied the acquired RAS plus polymorphisms on NS5A phosphoprotein by computational studies. OMV showed a higher affinity towards baseline and 93H/108 K mutant structure (follow‐up) with respect to 93H/R108 mutant structure (relapse) on phosphoprotein. By Molecular Dynamics simulations (MDs), structural information about the protein stability in presence of OMV were observed. According to our data, molecular modeling approach has proved to be a powerful method to evaluate the impact of these RASs plus specific amino acid (AA) changes on phosphoprotein.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29575060</pmid><doi>10.1002/jmv.25073</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-0880-8955</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0146-6615
ispartof Journal of medical virology, 2018-07, Vol.90 (7), p.1257-1263
issn 0146-6615
1096-9071
language eng
recordid cdi_proquest_miscellaneous_2018662766
source Wiley-Blackwell Read & Publish Collection
subjects Aged
Amino acid sequence
Anilides - pharmacology
Antiviral Agents - pharmacology
Carbamates - pharmacology
computational analysis
Computer applications
Computer simulation
docking
Dynamic stability
Failure analysis
HCV phosphoprotein
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - virology
Humans
Male
Models, Molecular
Molecular chains
Molecular dynamics
Molecular Dynamics Simulation
molecular dynamics simulations
Molecular modelling
Molecular structure
Mutation, Missense
Polymorphism
Polymorphism, Genetic
Proline
Proteins
Recurrence
resistance‐associated substitutions
Ribavirin
Ritonavir
Therapy
Treatment Failure
Valine
Viral Nonstructural Proteins - chemistry
Viral Nonstructural Proteins - genetics
Virology
title Real‐life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T13%3A04%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real%E2%80%90life%203D%20therapy%20failure:%20Analysis%20of%20NS5A%2093H%20RAS%20plus%20108%20K%20polymorphism%20in%20complex%20with%20ombitasvir%20by%20molecular%20modeling&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Marascio,%20Nadia&rft.date=2018-07&rft.volume=90&rft.issue=7&rft.spage=1257&rft.epage=1263&rft.pages=1257-1263&rft.issn=0146-6615&rft.eissn=1096-9071&rft_id=info:doi/10.1002/jmv.25073&rft_dat=%3Cproquest_cross%3E2018662766%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3533-8d184a22221407a77f722adac65bff63d378a21b0b47263149572c6f9a6ac4573%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2047430817&rft_id=info:pmid/29575060&rfr_iscdi=true